These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24135276)

  • 1. EGFR and EGFRvIII in glioblastoma: partners in crime.
    Zadeh G; Bhat KP; Aldape K
    Cancer Cell; 2013 Oct; 24(4):403-4. PubMed ID: 24135276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.
    Fan QW; Cheng CK; Gustafson WC; Charron E; Zipper P; Wong RA; Chen J; Lau J; Knobbe-Thomsen C; Weller M; Jura N; Reifenberger G; Shokat KM; Weiss WA
    Cancer Cell; 2013 Oct; 24(4):438-49. PubMed ID: 24135280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
    Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
    Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma.
    Blomquist MR; Eghlimi R; Beniwal A; Grief D; Nascari DG; Inge L; Sereduk CP; Tuncali S; Roos A; Inforzato H; Sharma R; Pirrotte P; Mehta S; Fortin Ensign SP; Loftus JC; Tran NL
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway.
    de la Iglesia N; Konopka G; Puram SV; Chan JA; Bachoo RM; You MJ; Levy DE; Depinho RA; Bonni A
    Genes Dev; 2008 Feb; 22(4):449-62. PubMed ID: 18258752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes.
    Lo HW; Cao X; Zhu H; Ali-Osman F
    Mol Cancer Res; 2010 Feb; 8(2):232-45. PubMed ID: 20145033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma.
    An Z; Knobbe-Thomsen CB; Wan X; Fan QW; Reifenberger G; Weiss WA
    Cancer Res; 2018 Dec; 78(24):6785-6794. PubMed ID: 30401716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of glioblastoma tumorigenesis by feed-forward cytokine signaling.
    Jahani-Asl A; Yin H; Soleimani VD; Haque T; Luchman HA; Chang NC; Sincennes MC; Puram SV; Scott AM; Lorimer IA; Perkins TJ; Ligon KL; Weiss S; Rudnicki MA; Bonni A
    Nat Neurosci; 2016 Jun; 19(6):798-806. PubMed ID: 27110918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.
    Roos A; Dhruv HD; Peng S; Inge LJ; Tuncali S; Pineda M; Millard N; Mayo Z; Eschbacher JM; Loftus JC; Winkles JA; Tran NL
    Mol Cancer Res; 2018 Jul; 16(7):1185-1195. PubMed ID: 29724813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.
    Latha K; Li M; Chumbalkar V; Gururaj A; Hwang Y; Dakeng S; Sawaya R; Aldape K; Cavenee WK; Bogler O; Furnari FB
    Int J Cancer; 2013 Feb; 132(3):509-20. PubMed ID: 22729867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma.
    Yeo AT; Jun HJ; Appleman VA; Zhang P; Varma H; Sarkaria JN; Charest A
    Oncogene; 2021 Apr; 40(15):2682-2696. PubMed ID: 33707748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COPI-Mediated Nuclear Translocation of EGFRvIII Promotes STAT3 Phosphorylation and PKM2 Nuclear Localization.
    Zhang M; Sun H; Deng Y; Su M; Wei S; Wang P; Yu L; Liu J; Guo J; Wang X; Han X; He Q; Shen L
    Int J Biol Sci; 2019; 15(1):114-126. PubMed ID: 30662352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
    Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
    Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets.
    Cenciarelli C; Marei HE; Zonfrillo M; Casalbore P; Felsani A; Giannetti S; Trevisi G; Althani A; Mangiola A
    Oncotarget; 2017 Mar; 8(11):17873-17886. PubMed ID: 28157712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
    Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
    J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIM59 Promotes Gliomagenesis by Inhibiting TC45 Dephosphorylation of STAT3.
    Sang Y; Li Y; Song L; Alvarez AA; Zhang W; Lv D; Tang J; Liu F; Chang Z; Hatakeyama S; Hu B; Cheng SY; Feng H
    Cancer Res; 2018 Apr; 78(7):1792-1804. PubMed ID: 29386185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma.
    Nishikawa R; Sugiyama T; Narita Y; Furnari F; Cavenee WK; Matsutani M
    Brain Tumor Pathol; 2004; 21(2):53-6. PubMed ID: 15700833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ΔEGFR.
    Chumbalkar V; Latha K; Hwang Y; Maywald R; Hawley L; Sawaya R; Diao L; Baggerly K; Cavenee WK; Furnari FB; Bogler O
    J Proteome Res; 2011 Mar; 10(3):1343-52. PubMed ID: 21214269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma.
    Guo G; Gong K; Ali S; Ali N; Shallwani S; Hatanpaa KJ; Pan E; Mickey B; Burma S; Wang DH; Kesari S; Sarkaria JN; Zhao D; Habib AA
    Nat Neurosci; 2017 Aug; 20(8):1074-1084. PubMed ID: 28604685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.